Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned 1:1 to 1 dose of PRV-003 or placebo for five consecutive days,” the article reads. “Evaluated by the Safety Review Committee, no serious adverse events were recorded, and all patients demonstrated normal vital signs, electrocardiogram readings and breathing function. In total, the phase 1 trial was designed with six cohorts comprised of eight individuals each, with data expected to be reported after each cohort is completed.”
“After reviewing the data from MAD Cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high-dose MAD portion of the phase 1 clinical trial. We have unanimously approved the start of MAD Cohort II,” Dallas Hack, MD, member of the Safety Review Committee, said in a statement.* “The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.”
To view the full article, visit https://ibn.fm/uwump
About Odyssey Health Inc. (formerly Odyssey Group International Inc.)
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
*Odyssey Health achieves positive safety outcomes for concussion drug in multiple ascending dosing trial. Odyssey Health. August 18, 2022. Accessed August 23, 2022. https://www.globenewswire.com/news-release/2022/08/18/2500777/0/en/Odyssey-Health-Achieves-Positive-Safety-Outcomes-for-Concussion-Drug-in-Multiple-Ascending-Dosing-Trial.html
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
